Yaral Pharma, the US generics subsidiary of IBSA, a multinational pharmaceutical company headquartered in Lugano, Switzerland, launched in the U.S.
The company will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023. Yaral Pharma’s current portfolio includes products across a range of therapeutic areas, including pain and endocrinology. It plans to rapidly expand its product line and therapeutic areas of focus through outside opportunities and external partnerships.